Viatris Inc. to Release First Quarter 2021 Financial Results on May 10, 2021

Rhea-AI Summary

Viatris Inc. (NASDAQ: VTRS) will release its first quarter 2021 financial results on May 10, 2021, prior to the U.S. market opening. A webcast will follow at 10 a.m. ET to discuss these results, accessible at investor.viatris.com or via phone at 855.493.3607. Viatris formed in November 2020, merging Mylan and Pfizer's Upjohn. The company aims to improve global health access with a portfolio of over 1,400 approved molecules and operates in over 165 countries.

Positive

• Viatris is set to release its financial results, indicating ongoing business operations.
• The company reported a portfolio of over 1,400 approved molecules, highlighting its substantial product offerings.

Negative

• None.

PITTSBURGH, April 12, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its first quarter 2021 financial results on Monday, May 10, before the open of the U.S. financial markets. The company also will host a webcast at 10 a.m. ET on May 10 to discuss the results.

Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 855.493.3607 or 346.354.0950 for international callers (ID#: 3557756).  A replay of the webcast also will be available on the website.

About Viatris 
Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway^®. Formed in November 2020 through the combination of Mylan and Pfizer's Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube. 

Contacts:

Media:
+1.724.514.1968
Communications@viatris.com 

Jennifer Mauer
Head of Global Communications and Corporate Brand
Jennifer.Mauer@viatris.com

Investors:
+1.724.514.1813
InvestorRelations@viatris.com 

Bill Szablewski
Head of Capital Markets
William.Szablewski@viatris.com

Melissa Trombetta
Head of Investor Relations
Melissa.Trombetta@viatris.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/viatris-inc-to-release-first-quarter-2021-financial-results-on-may-10-2021-301266422.html

SOURCE Viatris Inc.

FAQ

When will Viatris release its first quarter 2021 financial results?

Viatris will release its first quarter 2021 financial results on May 10, 2021.

What time is the Viatris webcast for its financial results?

The webcast for Viatris' financial results is scheduled for 10 a.m. ET on May 10, 2021.

Where can I listen to Viatris' financial results webcast?

You can listen to the webcast at investor.viatris.com or by calling 855.493.3607.

What is Viatris' stock symbol?

Viatris is traded under the stock symbol VTRS.

What significant milestone did Viatris achieve in November 2020?

Viatris was formed through the merger of Mylan and Pfizer's Upjohn business in November 2020.